Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Completion of Acquisition or Disposition of Assets
TERN logo

Merck Completes Acquisition of Terns Pharmaceuticals Following 86.36% Share Tender

TERN8-KFiling Date: 5/5/2026
Terns Pharmaceuticals, Inc.
Description

What this story covers

Terns Pharmaceuticals is now a wholly owned subsidiary of Merck after a successful tender offer and merger. The deal involved a complete leadership overhaul, delisting from Nasdaq, and integrating Terns' oncology pipeline into Merck’s global infrastructure.

Story snapshot

CompanyTerns Pharmaceuticals, Inc.
TickerTERN
VariantStandard detailed
Duration13:03
Filing type8-K
PeriodAnnual 2026
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-205305
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in